Navigation Links
MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
Date:8/19/2007

Three Independent Clinical Trials Initiated with Teplizumab Manufactured at

MacroGenics

ROCKVILLE, Md., Aug. 2 /PRNewswire/ -- MacroGenics, Inc. announced today that its Protege trial is actively enrolling adults and children ages 8 to 35 with recent-onset type 1 diabetes. The global Phase 2/3 clinical trial will evaluate the safety and efficacy of three teplizumab dosing regimens administered at the start of the study and again at six months in individuals who are up to 12 weeks from their diagnosis of type 1 diabetes. "The initiation of the pivotal Protege study is an important milestone for MacroGenics and for the type 1 diabetes research community," stated Dr. Scott Koenig, President and CEO of MacroGenics. "It is also notable that teplizumab is the first CD3 monoclonal therapy targeting type 1 diabetes to reach this stage of clinical development."

Specifically, the Protege study will assess the ability of teplizumab to inhibit the autoimmune attack that destroys insulin-producing pancreatic beta cells in individuals with type 1 diabetes. If teplizumab is effective and has the ability to preserve or protect beta cells of the pancreas, patients may require less injected insulin and their blood glucose levels may be easier to control. Other research has shown that greater control of blood glucose levels can lead to better long-term health outcomes for patients with type 1 diabetes.

Dr. Koenig also commented, "We are pleased to announce that Dr. Kevan Herold of Yale University and Dr. Bernhard Hering of the University of Minnesota are leading additional teplizumab studies in type 1 diabetes." The AbATE and Delay studies, led by Dr. Herold, are evaluating the safety and efficacy of teplizumab in patients who have had the disease for up to one year. Dr. Hering is evaluating the use of teplizumab as an induction therapy in pancreatic islet cell transplantation.

Additional information regarding the studies i
'/>"/>

SOURCE MacroGenics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
4. Global Rabies Treatment May be Possible with NanoViricides Drugs
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 27, 2015  Finesse expands office in ... announced the expansion of its operations in ... mid-March and access for customers is expected shortly afterward. ... located adjacent to the current office, the new premises ... team and allow Finesse to bring on more service ...
(Date:2/26/2015)... 2015  Today the National Safety Council ... physical side effects of pain medications , ... Vicodin and Oxycontin, are safer options than over-the-counter pain ... painkillers than on heroin and cocaine combined," said ... "Yet, these medications are marketed as the Cadillac option ...
(Date:2/26/2015)... Legislation passed today by the House Ways and Means ... prescriptions in Medicare Part D from crossing the pharmacy ... (PIMA) of 2014 , introduced by Ways and Means ... Ranking Member Jim McDermott (D-WA), recognizes the need to ... right policies, said the Pharmaceutical Care Management Association (PCMA). ...
Breaking Medicine Technology:New Finesse Office in United Kingdom 2National Safety Council: Opioid prescription painkillers have hidden, deadly side effects 2PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2
... - NEOPHARM, Inc.,(Nasdaq: NEOL) today reported findings ... metastatic colorectal cancer patients with its,drug product ... While the interim analysis of data following ... patients demonstrated,disease stabilization, the study did not ...
... OTCBB: CHKT, VANCOUVER, April 02, 2007 /PRNewswire-FirstCall/ ... biotechnology company,developing chemokine-based therapies to treat cancer, ... the,University of Texas M. D. Anderson Cancer ... metastasis with a CXCR4,antagonist in a mouse ...
Cached Medicine Technology:NeoPharm Provides Update on LE-SN38 Program 2M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting 2M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting 3M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting 4
(Date:2/28/2015)... The noted Friedman Dental Group of South Florida ... their website. The new version of the site is ... section about their team members. Potential and current patients ... each Friedman Dental Group team member including new staff. ... provide our patients with the opportunity to get to ...
(Date:2/28/2015)... Developers of FCPX plugins and theme templates ... Final Cut Pro X entitled FCPX Overlay Chromatic Grunge 6K ... total control over 6k lens dirt overlays inside Final Cut ... “FCPX Overlay Chromatic was professionally designed to add level of ... Overlay Chromatic Grunge 6K is a resourceful tool from Pixel ...
(Date:2/28/2015)... 2015 “ Powermod ” was featured on ... a look at the latest and coolest technology products and ... NewsWatch and a technology expert, conducted the review and shared ... solutions. , Getting stuck with a low battery and no ... that people face on a daily basis. Even when a ...
(Date:2/28/2015)... Memphis, TN: MedixSafe has retracted a previous ... security reader named Guardian 2. The correct product ... biometric scanner that significantly increases the complexity of ... biometric scanner provides fast and easy access for ... narcotics lockers with Vanguard technology tracks inventory ...
(Date:2/28/2015)... My Shiney Hiney® LLC., the renowned brand ... Las Vegas, Nevada for the annual ASD Market Week tradeshow. ... leading consumer-goods tradeshows and My Shiney Hiney will be one ... Shiney Hiney can be found at booth number C1663. , ... at-home personal hygiene brush and cleansing system exclusively created to ...
Breaking Medicine News(10 mins):Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2
... McGovern Institute for Brain Research will head an ambitious ... dyslexia, supported by a $8.5M grant from the Ellison ... Gabrieli, are prominent experts in neuroimaging and human brain ... that first appear in early childhood. Autism impairs social ...
... (Pink Sheets: HRAL)-,HearAtLast Holdings, Inc. is proud to announce ... WMT ) to open its 17th hearing-aid,clinic to ... 450,Stevenson Road South, Oshawa, Ontario. The clinic officially opened ... the HearAtLast chain. The,Company currently owns and operates 16 ...
... Prefer to Store,Their Supplements in the Kitchen Cabinet, ... minerals, and other supplements? Is it the kitchen cabinet, ... bathroom cabinet,possibly next to the toothpaste and dental floss? ... and stash of granola bars and M&Ms,for those rainy ...
... running for office in 2008 should commit to an agenda ... that is second to none the American College of Physicians ... of the Nations Health Care. In its report, ACP offers ... support a series of recommendations. , The recommendations result from ...
... Imaging to Deliver ... Exceptional Accuracy, CHARLESTON, S.C., ... Medical University of South Carolina,s Hollings,Cancer Center have partnered to bring ... The TomoTherapy Hi-Art Treatment System is one of two available ...
... Jan. 31 Horace Mann,Educators Corporation (NYSE: HMN ... February 6, 2008 after the market closes. The,earnings press ... section of the Company,s website at http://www.horacemann.com .,Management ... results on,Thursday, February 7, 2008 at 10:00 a.m. ET., ...
Cached Medicine News:Health News:MIT's McGovern Institute researchers awarded $8.5M to study brain basis of autism and dyslexia 2Health News:HearAtLast Expands Chain to 17 Locations, Opening New Clinic in Oshawa, Ontario Wal-Mart Supercenter # 1056 2Health News:HearAtLast Expands Chain to 17 Locations, Opening New Clinic in Oshawa, Ontario Wal-Mart Supercenter # 1056 3Health News:HearAtLast Expands Chain to 17 Locations, Opening New Clinic in Oshawa, Ontario Wal-Mart Supercenter # 1056 4Health News:Finding the Right Home for Your Vitamins and Other Supplements 2Health News:Finding the Right Home for Your Vitamins and Other Supplements 3Health News:Achieving a US health care system 'second to none' 2Health News:Achieving a US health care system 'second to none' 3Health News:Achieving a US health care system 'second to none' 4Health News:MUSC's Hollings Cancer Center, Ralph H. Johnson VA Medical Center Partner on New TomoTherapy Treatment for Cancer Patients 2Health News:Horace Mann Announces Fourth Quarter Earnings Release and Conference Call 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: